Skip to main content
SpringerLink
Log in

Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Reactivation of hepatitis B virus (HBV) infection may occur in adult T-cell leukemia–lymphoma (ATL) patients with resolved HBV infection who receive monotherapy with the anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab. However, there is little evidence regarding the incidence and characteristics of HBV reactivation in ATL patients receiving systemic chemotherapy, including the use of this antibody. We conducted a retrospective study for 24 ATL patients with resolved HBV infection underwent regular HBV DNA monitoring to assess HBV reactivation in Nagoya City University Hospital between January 2005 and June 2013. With median HBV DNA follow-up of 238 days (range 57–1420), HBV reactivation (defined as the detection of HBV DNA) was observed in three (12.5 %) of 24 patients with resolved HBV infection. No hepatitis due to HBV reactivation occurred in those patients who were diagnosed with HBV DNA levels below 2.1 log copies/mL and who received antiviral drugs. Mogamulizumab was administered prior to HBV reactivation in two of three HBV-reactivated patients. In the mogamulizumab era, further well-designed prospective studies are warranted to estimate the incidence of HBV reactivation and to establish regular HBV DNA monitoring-guided preemptive antiviral therapy for such patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

HBV:

Hepatitis B virus

ATL:

Adult T-cell leukemia–lymphoma

HBsAg:

Hepatitis B surface antigen

Anti-HBc:

Antibodies against hepatitis B core antigen

Anti-HBs:

Antibodies against hepatitis B surface antigen

CCR4:

CC chemokine receptor 4

References

  1. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182–8.

    CAS  PubMed  Google Scholar 

  2. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59–68.

    Article  CAS  PubMed  Google Scholar 

  3. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605–11 (Epub 2008/12/17).

    Article  CAS  PubMed  Google Scholar 

  4. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90(1):13–23 (Epub 2009/06/23).

    Article  CAS  PubMed  Google Scholar 

  5. Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol. 2011;46(1):9–16 (Epub 2010/10/07).

    Article  CAS  PubMed  Google Scholar 

  6. Mitka M. FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA. 2013;310(16):1664.

    Article  CAS  PubMed  Google Scholar 

  7. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625–34.

    CAS  PubMed  Google Scholar 

  8. Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520–31.

    Article  CAS  PubMed  Google Scholar 

  9. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia–lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591–8.

    Article  CAS  PubMed  Google Scholar 

  10. Ishida T, Ueda R. Antibody therapy for Adult T-cell leukemia–lymphoma. Int J Hematol. 2011;94(5):443–52.

    Article  CAS  PubMed  Google Scholar 

  11. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia–lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42.

    Article  CAS  PubMed  Google Scholar 

  12. Motohashi K, Suzuki T, Kishimoto K, Numata A, Nakajima Y, Tachibana T, et al. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2013;98(2):258–60.

    Article  PubMed  Google Scholar 

  13. Nakano N, Kusumoto S, Tanaka Y, Ishida T, Takeuchi S, Takatsuka Y, et al. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia–lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2014;44(3):354–7.

    Article  CAS  PubMed  Google Scholar 

  14. Shin IT, Tanaka Y, Tateno Y, Mizokami M. Development and public release of a comprehensive hepatitis virus database. Hepatol Res. 2008;38(3):234–43.

    Article  Google Scholar 

  15. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59(6):2092–100.

    Article  CAS  PubMed  Google Scholar 

  16. Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Prospective nationwide observational study of hepatitis B virus (HBV) DNA monitoring and preemptive antiviral therapy for HBV reactivation in patients with B-cell non-Hodgkin lymphoma following rituximab containing chemotherapy: results of interim analysis. Blood. 2012; 120(21):abstract 2641.

  17. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia–lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458–64.

    Article  CAS  PubMed  Google Scholar 

  18. Jo T, Ishida T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia–lymphoma (ATL). J Clin Oncol 2013; 31: (suppl; abstr 8506).

  19. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci. 2011;102(1):44–50.

    Article  CAS  PubMed  Google Scholar 

  20. Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42(7):627–36 Epub 2012/06/13.

    Article  CAS  PubMed  Google Scholar 

  21. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85 Epub 2012/03/23.

    Article  Google Scholar 

Download references

Acknowledgments

We would like to thank staff as follows: Ms. Chiori Fukuyama and Dr. Shintaro Ogawa (Nagoya City University Graduate School of Medical Sciences, Nagoya) for keeping and measurement of specimens on this study. We also thank Dr. Shiro Akinaga (Kyowa Hakko Kirin Co., Ltd., Tokyo) for his enlightening advice on this article. This study was supported in part by the Ministry of Health, Labour and Welfare of Japan (grant-in-aid H24-kanen-004 to M.M.) and the Ministry of Education, Culture, Sports Science and Technology of Japan (grant-in-aid for Scientific Research (C) No. 24591428 to S.K.) and grant-in-aid for National Cancer Center Research and Development Fund (No. 26-A-4 to T.I.).

Conflict of interest

Shigeru Kusumoto received Research funding and honoraria from Kyowa Hakko Kirin Co., Ltd., and honoraria from Bristol-Myers Squibb. Takashi Ishida received research funding from Kyowa Hakko Kirin Co., Ltd., Bayer Pharma AG, and Celgene K.K. Ryuzo Ueda received research funding from Kyowa Hakko Kirin Co., Ltd. Yasuhito Tanaka received research funding from Bristol-Myers Squibb, and honoraria from Bristol-Myers Squibb. Shinsuke Iida received research funding from Kyowa Hakko Kirin Co., Ltd.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan

    Haruhito Totani, Shigeru Kusumoto, Takashi Ishida, Arisa Masuda, Takashi Yoshida, Asahi Ito, Masaki Ri, Hirokazu Komatsu & Shinsuke Iida

  2. Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    Shuko Murakami & Yasuhito Tanaka

  3. The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan

    Masashi Mizokami

  4. Department of Tumor Immunology, Aichi Medical University School of Medicine, Aichi, Japan

    Ryuzo Ueda

  5. Department of Respiratory Medicine, Allergy and Rheumatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    Akio Niimi

  6. Department of Anatomic Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    Hiroshi Inagaki

Authors
  1. Haruhito Totani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigeru Kusumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arisa Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Asahi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masaki Ri
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hirokazu Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shuko Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masashi Mizokami
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ryuzo Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Akio Niimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hiroshi Inagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yasuhito Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Shinsuke Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeru Kusumoto.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Totani, H., Kusumoto, S., Ishida, T. et al. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy. Int J Hematol 101, 398–404 (2015). https://doi.org/10.1007/s12185-015-1750-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-015-1750-z

Keywords

Search

Navigation